MAPT and Alzheimer disease: However, although Tau1 was the most relevant antibody to use in this context, Tau isforms other than those recognized by Tau1 have also been observed in the nucleus of neurons (18,63) and could display patterns of genome occupancy different from those determined here using the Tau1 antibody, such as oligomerized forms of Tau recognized by the TOC1 antibody as well as Tau phosphorylated at residues 212 and 214 and recognized by the AT100 antibody, whose nuclear accumulation varies with age and the AD-related Tau pathological state of neurons (18,63).